2020 HIV Drug Therapy Glasgow*

Hear insights from  Renslow Sherer, MD, on some of the most important data reported at the 2020 International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2020 Virtual), including new findings on long-term 2-drug and 3-drug antiretroviral therapy, the efficacy of newer 3-drug regimens in patients with baseline NRTI resistance, the latest information on investigational HIV treatment approaches, and updates on important comoribidities in patients with HIV, including COVID-19.

Renslow Sherer, MD Released: October 22, 2020

Preliminary evidence from the open-label STAT study suggests that the 2-drug regimen DTG/3TC may be a safe and effective choice for rapid-start ART. Here’s my take on what we learned from this HIV Glasgow report.

Eric S. Daar, MD Released: December 4, 2020

In this downloadable slideset, CCO’s expert faculty members summarize key studies from this important conference, including new data on current ART options, investigational ART strategies, and comorbidities.

Monica Gandhi, MD, MPH Renslow Sherer, MD Released: October 23, 2020

Experts review new study data from HIV Glasgow 2020 on current and emerging ART options as well as comorbidity management that will affect practice for international clinicians managing HIV patient care around the world.

Marina Klein, MD, MSc, FRCP(C) Jean-Michel Molina, MD, PhD Released: November 6, 2020

New data from HIV Glasgow 2020 demonstrate the utility and durability of the 2-drug regimen DTG/3TC.

Pedro Cahn, MD, PhD Released: November 6, 2020

Here’s what I found to be most interesting about the new data on investigational ARV drugs with the potential for long-acting use presented at HIV Glasgow 2020 Virtual and what I think we still need to learn.

Alexandra Calmy, MD, FMH, PhD Released: November 11, 2020